Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial

Detalles Bibliográficos
Autores principales: Sano, Daisuke, Oridate, Nobuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248579/
https://www.ncbi.nlm.nih.gov/pubmed/37304541
http://dx.doi.org/10.21037/tcr-23-48
_version_ 1785055407369093120
author Sano, Daisuke
Oridate, Nobuhiko
author_facet Sano, Daisuke
Oridate, Nobuhiko
author_sort Sano, Daisuke
collection PubMed
description
format Online
Article
Text
id pubmed-10248579
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-102485792023-06-09 Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial Sano, Daisuke Oridate, Nobuhiko Transl Cancer Res Editorial Commentary AME Publishing Company 2023-04-14 2023-05-31 /pmc/articles/PMC10248579/ /pubmed/37304541 http://dx.doi.org/10.21037/tcr-23-48 Text en 2023 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Sano, Daisuke
Oridate, Nobuhiko
Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
title Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
title_full Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
title_fullStr Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
title_full_unstemmed Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
title_short Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
title_sort long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the keynote-048 trial
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248579/
https://www.ncbi.nlm.nih.gov/pubmed/37304541
http://dx.doi.org/10.21037/tcr-23-48
work_keys_str_mv AT sanodaisuke longtermefficacyofimmunecheckpointinhibitorswithorwithoutchemotherapyinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckacommentaryonthe4yearfollowupofthekeynote048trial
AT oridatenobuhiko longtermefficacyofimmunecheckpointinhibitorswithorwithoutchemotherapyinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckacommentaryonthe4yearfollowupofthekeynote048trial

Ejemplares similares